In this Journal Club, Terrazas and Peón discuss a study that identifies a recurrent CTNNB1 mutation that generates shared neoantigens amenable to engineered T cell receptor (TCR)-T cell recognition. The work demonstrates potent antitumour activity across models and highlights the potential of targeting public mutations to broaden TCR-T cell immunotherapy for solid tumours.